# Next Generation Rocklatan

> **NCT06441643** · PHASE2 · COMPLETED · sponsor: **Alcon Research** · enrollment: 426 (actual)

## Conditions studied

- Open Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** AR-17043 Ophthalmic Solution
- **DRUG:** PG043 Ophthalmic Solution
- **DRUG:** Latanoprost 0.005% Ophthalmic Solution
- **DRUG:** Netarsudil 0.02% Ophthalmic Solution
- **DRUG:** Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution
- **DRUG:** AR-17043 Vehicle

## Key facts

- **NCT ID:** NCT06441643
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-04
- **Primary completion:** 2025-11-14
- **Final completion:** 2025-11-14
- **Target enrollment:** 426 (ACTUAL)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06441643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06441643, "Next Generation Rocklatan". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06441643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*